Single-Dose HPV Vaccine Highly Effective, New Study Finds – A Potential Game Changer for Global Cancer Prevention
A groundbreaking analysis published in the New England Journal of Medicine suggests a single dose of the human papillomavirus (HPV) vaccine offers protection comparable to the standard two-dose schedule, potentially revolutionizing cervical cancer prevention efforts worldwide.
The highly prevalent HPV, a common sexually transmitted infection, often resolves on its own. However, certain strains can lead to genital warts and, critically, pre-malignant lesions that can develop into cancer – most notably cervical cancer. Over 100 strains of HPV exist, with 14 classified as high-risk for cancer, with strains 16 and 18 being the most concerning. Currently available vaccines effectively protect against these strains, reducing the risk of HPV-related cancers.
The new research, conducted by the U.S. National Cancer Institute in collaboration with the Costa Rica Agency for Biomedical Research, tracked over 20,000 girls aged 12 to 16. Participants were randomly assigned to receive either a single dose or two doses of either a bivalent or nonavalent HPV vaccine. After six months, half of the girls received a second dose, while the other half received a pediatric vaccine unrelated to HPV as a control. Researchers followed the participants for five years, conducting regular gynecological check-ups focused on the most oncogenic HPV strains. A control group of 3,005 unvaccinated girls was also monitored for comparison.
The results were striking. Analysis revealed that a single dose of the HPV vaccine provided approximately 97% protection against HPV strains 16 and 18 – a performance level statistically equivalent to the two-dose schedule. “Statistical evaluation confirmed that one dose was non-inferior to two doses, with no significant differences in infection rates,” researchers found. Importantly, both vaccine types demonstrated a strong safety profile, with no adverse safety issues reported throughout the five-year follow-up period.
This finding carries significant implications, particularly for low-income countries where access to multiple vaccine doses can be a major barrier to widespread immunization. Simplifying the vaccination schedule to a single dose could dramatically increase coverage, reduce costs, and protect a larger number of girls and young women globally. While the study concentrated on cervical HPV infections, researchers emphasize the need for continued long-term monitoring to assess the vaccine’s effectiveness against other HPV-related cancers. Currently, less than a third of adolescent girls worldwide are vaccinated against HPV, highlighting the urgent need for improved access and uptake.
Further bolstering preventative measures, the European Union updated its cervical cancer screening recommendations in December 2022, prioritizing HPV testing for women aged 30 to 65 every five years, alongside ensuring vaccination for eligible individuals under the age of 15. HPV testing is demonstrably more effective than traditional cytology in accurately assessing cancer risk.
In Romania, access to HPV vaccination is expanding. As of October 1, 2025, insured individuals of all genders between the ages of 11 and 26 will receive full vaccine coverage, while women aged 27 to 45 will be eligible for 50% compensation. The vaccine will be available in pharmacies with a medical prescription and administered by qualified healthcare professionals, significantly enhancing cervical cancer prevention and reducing the incidence of HPV-associated cancers.
Adopting a single-dose HPV vaccination strategy could significantly accelerate cervical cancer prevention efforts worldwide, offering a practical and cost-effective solution to a global health challenge.
